Skip to content
LATEST
Health

ERβ phosphorylation at 3 sites may weaken brain signaling

The bioRxiv work offers an early molecular explanation for why estrogen-linked neuroprotective pathways may falter after menopause.

ERβ phosphorylation at 3 sites may weaken brain signaling

ERβ phosphorylation at three amino-acid sites reduced receptor pairing and weakened APP promoter repression in a bioRxiv preprint posted Nov. 17.

The work is early mechanistic evidence, not a patient study. It matters because estrogen receptor beta, or ERβ, helps coordinate gene activity tied to neuroprotection, while circulating estrogens fall after menopause.

Yoldas Yildiz, Jaroslava Seflova, Sarah Flury, Destiny Deschenes, Seth L. Robia and Toni R. Pak of Loyola University Chicago Stritch School of Medicine studied phosphorylation, a chemical modification of proteins, at ERβ-S176, S200 and Y488.

The authors used fluorescence lifetime measurements to quantify Förster resonance energy transfer, or FRET, a method for detecting close molecular interactions. They reported that phosphorylation at all three sites reduced ERβ homodimer formation, meaning the receptor was less able to pair with another ERβ molecule.

They also reported that phosphorylation at S200 and Y488 reduced ERβ-mediated repression of the amyloid precursor protein, or APP, promoter. A promoter is a gene-control region that helps regulate how strongly a gene is expressed.

The authors wrote that the findings suggest “age-dependent changes in ERβ phosphorylation result in decreased ERβ genomic signaling, which could reduce the neuroprotective effects of estrogens following menopause.”

The preprint frames the result against a clinical puzzle: hormone replacement therapy is described by the authors as beneficial only within a narrow window after the menopause transition. Their proposed mechanism is that age-related changes in protein interactions may limit ERβ’s genomic signaling later in life.

The study cannot show that changing ERβ phosphorylation would prevent cognitive decline, treat Alzheimer’s disease or restore estrogen signaling in people. The article is a bioRxiv preprint and has not been certified by peer review, and the abstract does not report a patient sample size or clinical outcome data.

The authors declared no competing interest. Funding was declared from the National Institutes of Health under grant 5R01AG082135.

Source: academic preprint, bioRxiv, Nov. 17, 2026.

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news